161 related articles for article (PubMed ID: 37838813)
1. Preoperative chemoradiotherapy induces multiple pathways related to anti-tumour immunity in rectal cancer.
Koukourakis IM; Xanthopoulou E; Sgouras TI; Kouroupi M; Giatromanolaki A; Kouloulias V; Tiniakos D; Zygogianni A
Br J Cancer; 2023 Nov; 129(11):1852-1862. PubMed ID: 37838813
[TBL] [Abstract][Full Text] [Related]
2. Chemoradiation-Induced Alteration of Programmed Death-Ligand 1 and CD8
Lim YJ; Koh J; Kim S; Jeon SR; Chie EK; Kim K; Kang GH; Han SW; Kim TY; Jeong SY; Park KJ; Wu HG
Int J Radiat Oncol Biol Phys; 2017 Dec; 99(5):1216-1224. PubMed ID: 29165286
[TBL] [Abstract][Full Text] [Related]
3. PD-L1 is upregulated by radiochemotherapy in rectal adenocarcinoma patients and associated with a favourable prognosis.
Hecht M; Büttner-Herold M; Erlenbach-Wünsch K; Haderlein M; Croner R; Grützmann R; Hartmann A; Fietkau R; Distel LV
Eur J Cancer; 2016 Sep; 65():52-60. PubMed ID: 27468145
[TBL] [Abstract][Full Text] [Related]
4. Radiation Therapy Promotes Hepatocellular Carcinoma Immune Cloaking via PD-L1 Upregulation Induced by cGAS-STING Activation.
Du SS; Chen GW; Yang P; Chen YX; Hu Y; Zhao QQ; Zhang Y; Liu R; Zheng DX; Zhou J; Fan J; Zeng ZC
Int J Radiat Oncol Biol Phys; 2022 Apr; 112(5):1243-1255. PubMed ID: 34986380
[TBL] [Abstract][Full Text] [Related]
5. Association between radiotherapy-induced alteration of programmed death ligand 1 and survival in patients with uterine cervical cancer undergoing preoperative radiotherapy.
Tsuchiya T; Someya M; Takada Y; Hasegawa T; Kitagawa M; Fukushima Y; Gocho T; Hori M; Nakata K; Hirohashi Y; Torigoe T; Saito T; Sakata KI
Strahlenther Onkol; 2020 Aug; 196(8):725-735. PubMed ID: 31953603
[TBL] [Abstract][Full Text] [Related]
6. Implication of programmed cell death ligand 1 expression in tumor recurrence and prognosis in rectal cancer with neoadjuvant chemoradiotherapy.
Saigusa S; Toiyama Y; Tanaka K; Inoue Y; Mori K; Ide S; Imaoka H; Kawamura M; Mohri Y; Kusunoki M
Int J Clin Oncol; 2016 Oct; 21(5):946-952. PubMed ID: 26919982
[TBL] [Abstract][Full Text] [Related]
7. Prognostic relevance of programmed cell death-ligand 1 expression and CD8+ TILs in rectal cancer patients before and after neoadjuvant chemoradiotherapy.
Chen TW; Huang KC; Chiang SF; Chen WT; Ke TW; Chao KSC
J Cancer Res Clin Oncol; 2019 Apr; 145(4):1043-1053. PubMed ID: 30874889
[TBL] [Abstract][Full Text] [Related]
8. Upregulation of tumor PD-L1 by neoadjuvant chemoradiotherapy (neoCRT) confers improved survival in patients with lymph node metastasis of locally advanced rectal cancers.
Chiang SF; Huang CY; Ke TW; Chen TW; Lan YC; You YS; Chen WT; Chao KSC
Cancer Immunol Immunother; 2019 Feb; 68(2):283-296. PubMed ID: 30448924
[TBL] [Abstract][Full Text] [Related]
9. Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy.
Sundara YT; Kostine M; Cleven AH; Bovée JV; Schilham MW; Cleton-Jansen AM
Cancer Immunol Immunother; 2017 Jan; 66(1):119-128. PubMed ID: 27853827
[TBL] [Abstract][Full Text] [Related]
10. Chemoradiation-induced alteration of programmed death-ligand 1, CD8+ tumor-infiltrating lymphocytes and mucin expression in rectal cancer.
Baretti M; Zhu Q; Fu W; Meyer J; Wang H; Anders RA; Azad NS
Oncotarget; 2022; 13():907-917. PubMed ID: 35937503
[TBL] [Abstract][Full Text] [Related]
11. Targeting two radiation-induced immunosuppressive pathways to improve the efficacy of normofractionated radiation therapy in a preclinical colorectal cancer model.
Boustani J; Lecoester B; Baude J; Latour C; Limagne E; Ladjohoulou R; Morgand V; Froidurot L; Ghiringhelli F; Truc G; Adotévi O; Mirjolet C
Int J Radiat Biol; 2024; 100(6):912-921. PubMed ID: 38506658
[TBL] [Abstract][Full Text] [Related]
12. The prognostic effect of neoadjuvant chemoradiotherapy on the change of PD-L1 expression in patients with locally advanced rectal adenocarcinoma.
Richter I; Jirasek T; Dvorak J; Cermakova E; Rehakova P; Bartos J
J BUON; 2017; 22(4):875-881. PubMed ID: 29155514
[TBL] [Abstract][Full Text] [Related]
13. Irradiation-induced IFN-type-I pathway activation in prostate cancer cell lines.
Xanthopoulou ET; Koukourakis IM; Kakouratos C; Nanos C; Kalaitzis C; Giatromanolaki A; Koukourakis MI
Cytokine; 2023 Sep; 169():156252. PubMed ID: 37301190
[TBL] [Abstract][Full Text] [Related]
14. Pattern of programmed cell death-ligand 1 expression and CD8-positive T-cell infiltration before and after chemoradiotherapy in rectal cancer.
Ogura A; Akiyoshi T; Yamamoto N; Kawachi H; Ishikawa Y; Mori S; Oba K; Nagino M; Fukunaga Y; Ueno M
Eur J Cancer; 2018 Mar; 91():11-20. PubMed ID: 29328976
[TBL] [Abstract][Full Text] [Related]
15. A combination of stromal PD-L1 and tumoral nuclear β-catenin expression as an indicator of colorectal carcinoma progression and resistance to chemoradiotherapy in locally advanced rectal carcinoma.
Takahashi H; Watanabe H; Hashimura M; Matsumoto T; Yokoi A; Nakagawa M; Ishibashi Y; Ito T; Ohhigata K; Saegusa M
J Pathol Clin Res; 2022 Sep; 8(5):458-469. PubMed ID: 35762092
[TBL] [Abstract][Full Text] [Related]
16. Programmed cell death ligand 1 expression on monocytes is inversely correlated with tumour response to preoperative chemoradiotherapy for locally advanced rectal cancer.
Tojo M; Horie H; Koinuma K; Miyato H; Tsukui H; Kaneko Y; Futoh Y; Kimura Y; Takahashi K; Saito A; Ohzawa H; Yamaguchi H; Lefor AK; Sata N; Kitayama J
Colorectal Dis; 2022 Oct; 24(10):1140-1149. PubMed ID: 35502766
[TBL] [Abstract][Full Text] [Related]
17. Somatic Mutations and Immune Alternation in Rectal Cancer Following Neoadjuvant Chemoradiotherapy.
Ji D; Yi H; Zhang D; Zhan T; Li Z; Li M; Jia J; Qiao M; Xia J; Zhai Z; Song C; Gu J
Cancer Immunol Res; 2018 Nov; 6(11):1401-1416. PubMed ID: 30282671
[TBL] [Abstract][Full Text] [Related]
18. PD-L1 and HLA-class I expression status and their therapeutic implication in oesophageal small-cell carcinoma.
Yamashita S; Abe H; Yamashita H; Yagi K; Seto Y; Ushiku T
Histopathology; 2023 Aug; 83(2):264-275. PubMed ID: 37071391
[TBL] [Abstract][Full Text] [Related]
19. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
20. Ataxia telangiectasia mutated kinase inhibition promotes irradiation-induced PD-L1 expression in tumour-associated macrophages through IFN-I/JAK signalling pathway.
Gao Y; Li Y; Lin Z; Zeng Y; Huang Z; Han L; Zhong Y; Gong Y; Wu Q; Xie C
Immunology; 2023 Feb; 168(2):346-361. PubMed ID: 36326481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
